Niagen Bioscience reported second quarter 2026 net sales of $29.8 million, missing analyst expectations, while diluted earnings per share came in at $0.01, meeting estimates. The results were driven by strong growth in the direct-to-consumer e-commerce business, which was offset by weakness in the company's B2B ingredient segment.
Key Highlights
- Direct-to-consumer sales, a key focus area, grew 23% year-over-year, accounting for the majority of sales for the flagship Tru Niagen product.
- Gross margin remained strong at 64.8%, reflecting a continued favorable business mix towards higher-margin direct sales.
- The company launched its Niagen Plus telehealth platform and introduced NB4168, a new therapeutic candidate for its pharmaceutical program, signaling investment in future growth drivers.
- Niagen Bioscience repurchased $2.8 million of its common stock during the quarter.